Cumberbatch M, North B, Kealy R, Smith S, Hubbard R, Kennish S
BMJ Open. 2025; 15(2):e096431.
PMID: 39933820
PMC: 11815428.
DOI: 10.1136/bmjopen-2024-096431.
Cheewadhanaraks S, Sereeborwornthanasak K, Siripongsatian D, Jantarato A, Promteangtrong C, Kunawudhi A
Nucl Med Mol Imaging. 2025; 59(1):79-90.
PMID: 39881967
PMC: 11772630.
DOI: 10.1007/s13139-024-00884-z.
Patel S, Antar A, Alrabaa A, Saffati G, Fleming B, Srikishen N
Life (Basel). 2025; 15(1).
PMID: 39859958
PMC: 11766662.
DOI: 10.3390/life15010017.
Zhang X, Pan J, Xu R, Fu Y, Lv B
Transl Androl Urol. 2024; 13(11):2625-2643.
PMID: 39698570
PMC: 11650338.
DOI: 10.21037/tau-24-514.
Kumar N
Cancer Control. 2024; 31:10732748241302863.
PMID: 39573923
PMC: 11583501.
DOI: 10.1177/10732748241302863.
Trends of prostate cancer treatment in Ehime Prefecture, Japan: analysis of a hospital-based cancer registry.
Hashine K, Yamashita N, Teramoto N
BMC Urol. 2024; 24(1):248.
PMID: 39521977
PMC: 11549837.
DOI: 10.1186/s12894-024-01646-x.
Changing times: trends in risk classification, tumor upstaging, and positive surgical margins after radical prostatectomy - results from a contemporary National Cancer Database study.
Freitas P, Blachman-Braun R, Soodana-Prakash N, Williams A, Ritch C, Punnen S
World J Urol. 2024; 42(1):551.
PMID: 39347950
PMC: 11442602.
DOI: 10.1007/s00345-024-05262-0.
Proficiency score as a predictor of early trifecta achievement during the learning curve of robot-assisted radical prostatectomy for high-risk prostate cancer: Results of a multicentric series.
Anceschi U, Flammia R, Tufano A, Morelli M, Galfano A, Luciani L
Curr Urol. 2024; 18(2):110-114.
PMID: 39176300
PMC: 11337992.
DOI: 10.1097/CU9.0000000000000213.
Treatment of intermediate-risk prostate cancer with active surveillance in the routine care-Long-term outcomes of a prospective noninterventional study (HAROW).
Weissbach L, Schwarte A, Boedefeld E, Herden J
Curr Urol. 2024; 18(2):115-121.
PMID: 39176297
PMC: 11337982.
DOI: 10.1097/CU9.0000000000000203.
Machine learning-driven mast cell gene signatures for prognostic and therapeutic prediction in prostate cancer.
Maimaitiyiming A, An H, Xing C, Li X, Li Z, Bai J
Heliyon. 2024; 10(15):e35157.
PMID: 39170129
PMC: 11336432.
DOI: 10.1016/j.heliyon.2024.e35157.
A Novel Liquid Biopsy Method Based on Specific Combinations of Vesicular Markers Allows Us to Discriminate Prostate Cancer from Hyperplasia.
Martorana E, Raciti G, Giuffrida R, Bruno E, Ficarra V, Ludovico G
Cells. 2024; 13(15.
PMID: 39120316
PMC: 11311686.
DOI: 10.3390/cells13151286.
Development of an effective predictive screening tool for prostate cancer using the ClarityDX machine learning platform.
Hyndman M, Paproski R, Kinnaird A, Fairey A, Marks L, Pavlovich C
NPJ Digit Med. 2024; 7(1):163.
PMID: 38902526
PMC: 11190196.
DOI: 10.1038/s41746-024-01167-9.
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
Lee W, Dignam J, Amin M, Bruner D, Low D, Swanson G
J Clin Oncol. 2024; 42(20):2377-2381.
PMID: 38759121
PMC: 11377096.
DOI: 10.1200/JCO.23.02445.
Benign prostatic hyperplasia during active surveillance for prostate cancer: is it time to define management strategies?.
Bologna E, Licari L, Ditonno F, Flammia R, Brassetti A, Leonardo C
Prostate Cancer Prostatic Dis. 2024; .
PMID: 38684917
DOI: 10.1038/s41391-024-00837-9.
Exploring the relation of active surveillance schedules and prostate cancer mortality.
Yang Z, Heijnsdijk E, Newcomb L, Rizopoulos D, Erler N
Cancer Med. 2024; 13(5):e6977.
PMID: 38491826
PMC: 10943374.
DOI: 10.1002/cam4.6977.
The Impact of Physical Activity on the Outcomes of Active Surveillance in Prostate Cancer Patients: A Scoping Review.
Brassetti A, Cacciatore L, Bove A, Anceschi U, Proietti F, Misuraca L
Cancers (Basel). 2024; 16(3).
PMID: 38339381
PMC: 10854832.
DOI: 10.3390/cancers16030630.
Positive family history as a predictor for disease outcomes after radical prostatectomy for nonmetastatic prostate cancer.
Rajwa P, Quhal F, DAndrea D, Korn S, Petrov P, Yanagisawa T
Arab J Urol. 2024; 21(4):241-247.
PMID: 38178943
PMC: 10763581.
DOI: 10.1080/2090598X.2023.2196911.
Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer.
Hu S, Chang C, Snyder J, Deshmukh V, Newman M, Date A
JCO Clin Cancer Inform. 2023; 7:e2300083.
PMID: 37988640
PMC: 10681553.
DOI: 10.1200/CCI.23.00083.
Location and Types of Treatment for Prostate Cancer After the Veterans Choice Program Implementation.
Erickson B, Hoffman R, Wachsmuth J, Packiam V, Vaughan-Sarrazin M
JAMA Netw Open. 2023; 6(10):e2338326.
PMID: 37856123
PMC: 10587787.
DOI: 10.1001/jamanetworkopen.2023.38326.
Active surveillance should be considered for select men with Grade Group 2 prostate cancer.
Pekala K, Bergengren O, Eastham J, Carlsson S
BMC Urol. 2023; 23(1):152.
PMID: 37777716
PMC: 10541702.
DOI: 10.1186/s12894-023-01314-6.
